Oncology Venture - A new regulatory strategy for dovitinib
Oncology Venture (OV) recently revealed its new regulatory strategy and clinical development plan for one of highest priority assets: dovitinib. OV will seek marketing approval for dovitinib based on prior data from Novartis demonstrating non-inferiority versus Nexavar (sorafenib, Bayer) for metastatic renal cell carcinoma (mRCC). Moreover, the company plans to run clinical trials utilising the new drug response predictor (DRP) for the combination of dovitinib + PD-1/PD-L1 to identify mRCC patients highly likely to respond and file a supplemental new drug application (sNDA).Oncology Venture A/S, formerly known as Medical Prognosis Institute A/S, is a Denmark-based company engaged in the development of anticancer medicines. It is primarily focused on the tool development for identification of patients with the highest probability of responding to a particular drug candidate, which increases the chance that the drug candidate is to be successful in clinical trials. The Company aims to improve the response rate of anticancer medicines whose clinical development has been suspended. After the clinical trials, the Company is to out-license or sell the drug candidates with a high response rate. The Company's main drug candidates are comprised of APO010, Irofulven and LiPlaCis.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.